Masimo (NASDAQ: MASI) is one of 46 publicly-traded companies in the “Electromedical equipment” industry, but how does it weigh in compared to its rivals? We will compare Masimo to similar companies based on the strength of its valuation, profitability, institutional ownership, risk, dividends, analyst recommendations and earnings.
Risk & Volatility
Masimo has a beta of 0.94, indicating that its share price is 6% less volatile than the S&P 500. Comparatively, Masimo’s rivals have a beta of 1.58, indicating that their average share price is 58% more volatile than the S&P 500.
Valuation and Earnings
This table compares Masimo and its rivals gross revenue, earnings per share (EPS) and valuation.
Masimo’s rivals have higher revenue, but lower earnings than Masimo. Masimo is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Insider and Institutional Ownership
82.8% of Masimo shares are held by institutional investors. Comparatively, 40.7% of shares of all “Electromedical equipment” companies are held by institutional investors. 16.6% of Masimo shares are held by company insiders. Comparatively, 20.1% of shares of all “Electromedical equipment” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
This is a breakdown of recent recommendations for Masimo and its rivals, as provided by MarketBeat.com.
||Strong Buy Ratings
Masimo presently has a consensus target price of $102.17, indicating a potential upside of 19.82%. As a group, “Electromedical equipment” companies have a potential upside of 19.55%. Given Masimo’s stronger consensus rating and higher probable upside, equities research analysts clearly believe Masimo is more favorable than its rivals.
This table compares Masimo and its rivals’ net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
Masimo beats its rivals on 8 of the 13 factors compared.
Masimo Company Profile
Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through-motion and low-perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry. It also provides Masimo rainbow SET platform that includes rainbow SET Pulse CO-Oximetry products that noninvasively monitor hemoglobin species, including oxygen saturation, pulse rate, perfusion index, pleth variability index, and respiration rate from the pleth; noninvasively monitor hemoglobin concentration, and carboxyhemoglobin and methemoglobin saturation; monitor arterial oxygen saturation and acoustic respiration rate; and calculates oxygen content and oxygen reserve index. In addition, the company offers SedLine brain function monitoring technology to measure the brain's electrical activity by detecting EEG signals; capnography and gas monitoring products comprising external plug-in-and-measure capnography and gas analyzers, integrated modules, and handheld capnograph and capnometer devices; and O3 regional oximetry for tissue oxygen saturation measurement. Further, it provides Patient SafetyNet, a surveillance, remote monitoring, and clinician notification solution; MyView, a wireless presence-detection system; and connectivity devices. The company provides its products directly, as well as through distributors and original equipment manufacturers partners to hospitals, emergency medical service providers, physician offices, veterinarians, long term care facilities, and consumers. Masimo Corporation has a strategic partnership with NU Hospitals. The company was founded in 1989 and is headquartered in Irvine, California.
Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.